Making multiple edits in a single step
A cell therapy candidate can require several genetic changes. HELIX® lets Qihan make multiple changes together and apply the same editing platform across different investigational programs.
Full platform nameHigh-throughput Engineering LIfe eXecuting editing
Disabling selected genes
A gene knockout disables a selected gene. Qihan reports achieving 62 gene knockouts in a single step with HELIX®.
Adding genetic material
A gene knock-in adds genetic material at a selected site. Qihan reports more than 12 gene knock-ins in a single step with the platform.
Assessing editing quality
Alongside editing efficiency, Qihan evaluates unintended edits and chromosome rearrangements. For QT-019B, Qihan reports rates of off-target editing and translocation at approximately 1% of the industry average it cites.
Research & development
QT-019B in clinical development
Qihan has applied HELIX® to several investigational products, including QT-019B, an allogeneic CAR-T candidate. The company reports investigational new drug clearances for QT-019B in the United States and China in 2025.
- Gene knockouts in one step
- 62
- Gene knock-ins in one step
- >12
- Reported translocation and off-target rates for QT-019B relative to the industry average
- 1%
- QT-019B IND clearances in the US and China
- 2025
